The content on this site is intended for healthcare professionals only
Dr Alison Birtle (Lancashire Teaching Hospitals, UK), Dr Ignacio Durán (Marques de Valdecilla University Hospital, Spain), Prof Evanguelos Xylinas (Bichat-Claude Bernard Hospital, France), Dr Giuseppe Simone (Regina Elena National Cancer Institute, Italy), and Dr Benjamin Pradere (La Croix Du Sud Hospital, France) discuss the latest updates in bladder cancer treatment for 2025.
The discussion highlights fresh trial data, evolving treatment strategies, and the importance of balancing medical outcomes with patients' quality of life.
Encouraging results are reported from trials such as CREST, ANZUP 1301, SunRISe-4, SunRISe-1 and NIAGARA.
The panel also review the FDA’s approval of TAR 200, explore advances in neoadjuvant approaches, and discuss the growing role of ctDNA analysis in guiding care.
| Thinking outside the box: Novel or unexpected data | |
| Latest in NMIBC | |
| Drug-device combination for NMIBC and MIBC | |
| Perioperative therapy in urothelial carcinoma | |
| Take home messages |
Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer
Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer
HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer
Latest in bladder cancer from the second half of 2025
Treatment management of favourable risk and very favourable risk patients
Key insights from head and neck research at ASCO 2025
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer
